Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

[1]  Borghi Claudio,et al.  Pulmonary Embolism in Patients with COVID-19 , 2022, Clinical Cardiology and Cardiovascular Interventions.

[2]  D. Wichmann.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[3]  C. S. Kow,et al.  Meta-analysis of Effect of Statins in Patients with COVID-19 , 2020, The American Journal of Cardiology.

[4]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[5]  P. Navalesi,et al.  Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit , 2020, Thrombosis and Haemostasis.

[6]  T. Woodruff,et al.  COVID-19: Complement, Coagulation, and Collateral Damage , 2020, The Journal of Immunology.

[7]  A. Tremoulet,et al.  Clinical management of multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) , 2020 .

[8]  L. Argaud,et al.  Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis , 2020, Journal of Thrombosis and Haemostasis.

[9]  W. Zuo,et al.  Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2 , 2020, American journal of respiratory and critical care medicine.

[10]  R. Favory,et al.  Pulmonary Embolism in Patients With COVID-19 , 2020, Circulation.

[11]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[12]  F. Hindilerden,et al.  Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case , 2020, Thrombosis Research.

[13]  J. DiNicolantonio,et al.  Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole , 2020, Medical Hypotheses.

[14]  C. D. Dela Cruz,et al.  Circulating Markers of Angiogenesis and Endotheliopathy in COVID-19 , 2020, medRxiv.

[15]  S. West,et al.  Improved survival following ward-based non-invasive pressure support for severe hypoxia in a cohort of frail patients with COVID-19: retrospective analysis from a UK teaching hospital , 2020, BMJ open respiratory research.

[16]  J. O’Donnell,et al.  Endothelial cells orchestrate COVID-19 coagulopathy , 2020, The Lancet Haematology.

[17]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[18]  David R. Holtgrave,et al.  Multisystem Inflammatory Syndrome in Children in New York State , 2020, The New England journal of medicine.

[19]  Y. Zhang,et al.  Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis , 2020, Circulation research.

[20]  Simon Li,et al.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents , 2020, The New England journal of medicine.

[21]  Robert A. Campbell,et al.  Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome , 2020, Blood.

[22]  S. Pittaluga,et al.  Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series , 2020, EClinicalMedicine.

[23]  J. Freedman,et al.  Platelets and Immunity: Going Viral. , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Robert A. Campbell,et al.  Platelet gene expression and function in patients with COVID-19 , 2020, Blood.

[25]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[26]  J. Atkinson,et al.  The complement system in COVID-19: friend and foe? , 2020, JCI insight.

[27]  F. Chollet,et al.  Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19 , 2020, British journal of haematology.

[28]  A. Combes,et al.  Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19–Associated Coagulopathy , 2020, Circulation.

[29]  P. Zachariah,et al.  Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. , 2020, JAMA.

[30]  Andrea Gianatti,et al.  Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.

[31]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[32]  Cheorl-Ho Kim.  SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus–Host Interaction , 2020, International journal of molecular sciences.

[33]  B. Gao,et al.  Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19 , 2020, Antioxidants.

[34]  R. Martino,et al.  Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19 , 2020, Annals of Hematology.

[35]  R. V. Vander Heide,et al.  Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans , 2020, The Lancet Respiratory Medicine.

[36]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[37]  P. Carmeliet,et al.  COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.

[38]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[39]  B. Gao,et al.  Nrf2 Activator PB125® as a Potential Therapeutic Agent Against COVID-19 , 2020, bioRxiv.

[40]  S. Zhang,et al.  Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients with Severe COVID-19 in Wuhan. , 2020, Circulation.

[41]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[42]  Russell M Viner,et al.  Kawasaki-like disease: emerging complication during the COVID-19 pandemic , 2020, The Lancet.

[43]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[44]  Yu Hu,et al.  Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome. , 2020, Circulation.

[45]  M. Merad,et al.  Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.

[46]  M. Aepfelbacher,et al.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[47]  S. Sivapalaratnam,et al.  Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 , 2020, The New England journal of medicine.

[48]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[49]  K. Mertz,et al.  Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction , 2020, Histopathology.

[50]  S. Dahan,et al.  Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France , 2020, Journal of the American Academy of Dermatology.

[51]  J. Fichet,et al.  Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.

[52]  P. Theocharis,et al.  Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.

[53]  Amit N. Patel,et al.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 , 2020, The New England journal of medicine.

[54]  A. Rocchi,et al.  Chilblain‐like lesions in children following suspected COVID‐19 infection , 2020, Pediatric dermatology.

[55]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[56]  D. Andreini,et al.  ST-Elevation Myocardial Infarction in Patients With COVID-19 , 2020, Circulation.

[57]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[58]  Thomas J Oxley,et al.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.

[59]  R. Bush,et al.  Acute limb ischemia in patients with COVID-19 pneumonia , 2020, Journal of Vascular Surgery.

[60]  Tong Li,et al.  Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China , 2020, Journal of Infection.

[61]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[62]  R. José,et al.  COVID-19 cytokine storm: the interplay between inflammation and coagulation , 2020, The Lancet Respiratory Medicine.

[63]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[64]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[65]  John D Lambris,et al.  Complement as a target in COVID-19? , 2020, Nature Reviews Immunology.

[66]  B. Drénou,et al.  Lupus anticoagulant is frequent in patients with Covid‐19 , 2020, Journal of Thrombosis and Haemostasis.

[67]  Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence , 2020 .

[68]  B. Ibáñez,et al.  The Obstacle Course of Reperfusion for ST-Segment–Elevation Myocardial Infarction in the COVID-19 Pandemic , 2020, Circulation.

[69]  P. Navalesi,et al.  COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure , 2020, Thrombosis and Haemostasis.

[70]  B. Ibáñez,et al.  The Obstacle Course of Reperfusion for ST-Segment–Elevation Myocardial Infarction in the COVID-19 Pandemic , 2020, Circulation.

[71]  Jincun Zhao,et al.  Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 , 2020, Acta Pharmaceutica Sinica B.

[72]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[73]  L. Beenen,et al.  Incidence of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[74]  Carl H. June,et al.  Cytokine release syndrome in severe COVID-19 , 2020, Science.

[75]  J. Connors,et al.  Thromboinflammation and the hypercoagulability of COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[76]  M. Yaffe,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A comment , 2020, Journal of Thrombosis and Haemostasis.

[77]  Yuan Yu,et al.  Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[78]  Binita Shah,et al.  ST-Segment Elevation in Patients with Covid-19 — A Case Series , 2020, The New England journal of medicine.

[79]  L. Menicanti,et al.  The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome , 2020, Journal of Thrombosis and Haemostasis.

[80]  G. Grasselli,et al.  Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.

[81]  David Berlin,et al.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.

[82]  B. Lämmle,et al.  Severe COVID-19 infection associated with endothelial activation , 2020, Thrombosis Research.

[83]  M. Dolhnikoff,et al.  Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[84]  E. Andrès,et al.  Immune Thrombocytopenic Purpura in a Patient with Covid-19 , 2020, The New England journal of medicine.

[85]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[86]  M. DeBaun.  Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic , 2020, Blood.

[87]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[88]  J. Q. Brown,et al.  Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans , 2020, medRxiv.

[89]  Subha Ghosh,et al.  COVID-19 Autopsies, Oklahoma, USA , 2020, American journal of clinical pathology.

[90]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[91]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[92]  W. Liang,et al.  Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 , 2020, The Lancet Haematology.

[93]  R. Kahwash,et al.  Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? , 2020, Circulation.

[94]  Xuetao Cao.  COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.

[95]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[96]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[97]  M. Huang,et al.  Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 , 2020, Journal of Thrombosis and Thrombolysis.

[98]  G. Lippi,et al.  D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis , 2020, Thrombosis and Haemostasis.

[99]  D. Diz,et al.  COVID-19, ACE2, and the cardiovascular consequences , 2020, American journal of physiology. Heart and circulatory physiology.

[100]  B. Lévy,et al.  Interaction between RAAS inhibitors and ACE2 in the context of COVID-19 , 2020, Nature Reviews Cardiology.

[101]  Jing Yuan,et al.  Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. , 2020, JAMA.

[102]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[103]  Roberto Maroldi,et al.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[104]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[105]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[106]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[107]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues , 2020, Cell.

[108]  Jie Zhang,et al.  Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis , 2020, Respiratory Research.

[109]  R. Liu,et al.  Prominent changes in blood coagulation of patients with SARS-CoV-2 infection , 2020, Clinical chemistry and laboratory medicine.

[110]  Mario Plebani,et al.  Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis , 2020, Clinica Chimica Acta.

[111]  R. Kacmarek,et al.  Protocol for a randomized controlled trial testing inhaled nitric oxide therapy in spontaneously breathing patients with COVID-19 , 2020, medRxiv.

[112]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[113]  K. Yuen,et al.  SARS-CoV-2 is an appropriate name for the new coronavirus , 2020, The Lancet.

[114]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[115]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[116]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[117]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[118]  Wenjie Yang,et al.  Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China , 2020, Journal of Infection.

[119]  王华英,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[120]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[121]  S. Zhang,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[122]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[123]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[124]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[125]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[126]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[127]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[128]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[129]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[130]  M. Petri,et al.  Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. , 2019, Blood.

[131]  A. Frost,et al.  Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents. , 2019, Chest.

[132]  Kanika Jain,et al.  Role of Platelet Mitochondria: Life in a Nucleus-Free Zone , 2019, Front. Cardiovasc. Med..

[133]  T. Kiss,et al.  Nrf2 dysfunction and impaired cellular resilience to oxidative stressors in the aged vasculature: from increased cellular senescence to the pathogenesis of age-related vascular diseases , 2019, GeroScience.

[134]  T. Kiss,et al.  Treatment with the poly(ADP-ribose) polymerase inhibitor PJ-34 improves cerebromicrovascular endothelial function, neurovascular coupling responses and cognitive performance in aged mice, supporting the NAD+ depletion hypothesis of neurovascular aging , 2019, GeroScience.

[135]  A. Hainsworth,et al.  Cyclic nucleotide phosphodiesterases (PDEs) and endothelial function in ischaemic stroke. A review. , 2019, Cellular signalling.

[136]  Kanika Jain,et al.  Author's response to “platelet antioxidants: A conundrum in aging” , 2019, EBioMedicine.

[137]  A. Walls,et al.  Structural basis for human coronavirus attachment to sialic acid receptors , 2019, Nature Structural & Molecular Biology.

[138]  T. Kiss,et al.  Nicotinamide mononucleotide (NMN) treatment attenuates oxidative stress and rescues angiogenic capacity in aged cerebromicrovascular endothelial cells: a potential mechanism for the prevention of vascular cognitive impairment , 2019, GeroScience.

[139]  Kanika Jain,et al.  Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients , 2019, EBioMedicine.

[140]  D. Barber,et al.  Understanding Platelets in Infectious and Allergic Lung Diseases , 2019, International journal of molecular sciences.

[141]  B. Chong,et al.  Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia , 2019, Nature Communications.

[142]  S. Jackson,et al.  Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. , 2019, Blood.

[143]  A. Weyrich,et al.  Megakaryocyte emperipolesis mediates membrane transfer from intracytoplasmic neutrophils to platelets , 2018, bioRxiv.

[144]  Jie Cui,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[145]  Toshiyuki Shimizu,et al.  Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands. , 2018, Cell reports.

[146]  B. Chong,et al.  Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia , 2018, Nature Communications.

[147]  E. Lefrançais,et al.  Platelet Biogenesis in the Lung Circulation , 2018, Blood.

[148]  V. Schulz,et al.  MRTFA augments megakaryocyte maturation by enhancing the SRF regulatory axis. , 2018, Blood advances.

[149]  Cory B. Giles,et al.  Endothelial dysfunction and angiogenesis impairment in the ageing vasculature , 2018, Nature Reviews Cardiology.

[150]  D. Garcia,et al.  Diagnosis and Management of the Antiphospholipid Syndrome , 2018, The New England journal of medicine.

[151]  C. Mineo,et al.  Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. , 2018, Blood.

[152]  F. Bozza,et al.  Platelets in Immune Response to Virus and Immunopathology of Viral Infections , 2018, Front. Med..

[153]  C. Aloui,et al.  The Non-Hemostatic Aspects of Transfused Platelets , 2018, Front. Med..

[154]  J. Freedman,et al.  Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis , 2018, Circulation research.

[155]  J. Cosemans,et al.  Platelet interaction with activated endothelium: mechanistic insights from microfluidics. , 2017, Blood.

[156]  Eric A. Hoffman,et al.  A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema‐like Lung Characteristics on CT Imaging: The MESA Lung Study , 2017, Chest.

[157]  E. Hawk,et al.  Platelet “first responders” in wound response, cancer, and metastasis , 2017, Cancer and Metastasis Reviews.

[158]  L. Lerman,et al.  Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. , 2017, Journal of the American College of Cardiology.

[159]  J. Al-Tawfiq,et al.  Hematologic, hepatic, and renal function changes in hospitalized patients with Middle East respiratory syndrome coronavirus , 2017, International journal of laboratory hematology.

[160]  K. Jurk,et al.  Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. , 2017, Blood.

[161]  E. Passegué,et al.  The lung is a site of platelet biogenesis and a reservoir for hematopoietic progenitors , 2017, Nature.

[162]  A. Weyrich,et al.  Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases. , 2016, Physiological reviews.

[163]  Yu Jin,et al.  Inducing mitophagy in diabetic platelets protects against severe oxidative stress , 2016, EMBO molecular medicine.

[164]  J. Hwa,et al.  Regulation of VWF expression, and secretion in health and disease , 2016, Current opinion in hematology.

[165]  Patty J. Lee,et al.  The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation. , 2016, Immunity.

[166]  H. Falet,et al.  Regulating billions of blood platelets: glycans and beyond. , 2015, Blood.

[167]  Qing Jun Wang,et al.  Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis. , 2015, Blood.

[168]  D. Hui,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[169]  Yi Xie,et al.  Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. , 2015, Blood.

[170]  E. Benjamin,et al.  Sex Differences in Platelet Toll-Like Receptors and Their Association With Cardiovascular Risk Factors , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[171]  E. Benjamin,et al.  Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. , 2014, Blood.

[172]  B. Furie,et al.  Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. , 2014, Blood.

[173]  G. Paré,et al.  Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation. , 2014, Blood.

[174]  Yu Jin,et al.  Aldose Reductase–Mediated Phosphorylation of p53 Leads to Mitochondrial Dysfunction and Damage in Diabetic Platelets , 2014, Circulation.

[175]  A. Arifi,et al.  Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. , 2014, Annals of internal medicine.

[176]  S. Sengupta,et al.  Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. , 2014, Blood.

[177]  Zhihua Chen,et al.  Dissection of autophagy in human platelets , 2014, Autophagy.

[178]  A. Weyrich,et al.  Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. , 2013, Blood.

[179]  Z. Memish,et al.  A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case , 2013, International Journal of Infectious Diseases.

[180]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[181]  Z. Memish,et al.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.

[182]  Ziad A Memish,et al.  Family cluster of Middle East respiratory syndrome coronavirus infections. , 2013, The New England journal of medicine.

[183]  R. Flaumenhaft,et al.  Platelet Granule Exocytosis: A Comparison with Chromaffin Cells , 2013, Front. Endocrinol..

[184]  S. Krilis,et al.  The pathogenesis of the antiphospholipid syndrome. , 2013, The New England journal of medicine.

[185]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[186]  J. Altman,et al.  Platelets support a protective immune response to LCMV by preventing splenic necrosis. , 2013, Blood.

[187]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[188]  P. Nigrovic,et al.  Platelets: active players in the pathogenesis of arthritis and SLE , 2012, Nature Reviews Rheumatology.

[189]  J. Orenstein,et al.  Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study , 2012, PloS one.

[190]  A. Weyrich,et al.  In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). , 2012, Chest.

[191]  P. Rabinovitch,et al.  Mitochondria and cardiovascular aging. , 2012, Circulation research.

[192]  K. Martin,et al.  Aldose Reductase, Oxidative Stress, and Diabetic Mellitus , 2012, Front. Pharmacol..

[193]  G. Lakos.  Interference in Antiphospholipid Antibody Assays , 2012, Seminars in Thrombosis & Hemostasis.

[194]  V. Leytin.  Apoptosis in the anucleate platelet. , 2012, Blood reviews.

[195]  L. Wen,et al.  Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. , 2011, The Journal of clinical investigation.

[196]  D. Seals,et al.  SIRT‐1 and vascular endothelial dysfunction with ageing in mice and humans , 2011, The Journal of physiology.

[197]  W. MacNee,et al.  Increased platelet activation in patients with stable and acute exacerbation of COPD , 2011, Thorax.

[198]  C. Midgett,et al.  Prostacyclin: An Inflammatory Paradox , 2011, Front. Pharmacol..

[199]  Jaime Gonzalez,et al.  The role of oxidative stress in the pathophysiology of hypertension , 2011, Hypertension Research.

[200]  F. Polack,et al.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes , 2010, Nature Medicine.

[201]  M. Leslie.  Cell biology. Beyond clotting: the powers of platelets. , 2010, Science.

[202]  C. Flaujac,et al.  Platelets and viruses: an ambivalent relationship , 2010, Cellular and Molecular Life Sciences.

[203]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[204]  E. Rimm,et al.  Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition , 2008, Circulation research.

[205]  Jordan S. Pober,et al.  Evolving functions of endothelial cells in inflammation , 2007, Nature Reviews Immunology.

[206]  G. Pierce,et al.  Direct Evidence of Endothelial Oxidative Stress With Aging in Humans: Relation to Impaired Endothelium-Dependent Dilation and Upregulation of Nuclear Factor-&kgr;B , 2007, Circulation research.

[207]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[208]  K. Ley,et al.  Platelet-neutrophil-interactions: linking hemostasis and inflammation. , 2007, Blood reviews.

[209]  Mikhail A Panteleev,et al.  Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets , 2007, Thrombosis and Haemostasis.

[210]  U. Förstermann,et al.  Endothelial Nitric Oxide Synthase in Vascular Disease: From Marvel to Menace , 2006, Circulation.

[211]  J. Kahn,et al.  History and Recent Advances in Coronavirus Discovery , 2005, The Pediatric infectious disease journal.

[212]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[213]  Chi-kong Li,et al.  Thrombocytopenia in patients with severe acute respiratory syndrome (review) , 2005, Hematology.

[214]  A. Zeiher,et al.  Endothelial Function: Cardiac Events , 2005, Circulation.

[215]  Chien-Liang Wu,et al.  Clinical and Laboratory Features of Severe Acute Respiratory Syndrome Vis-À-Vis Onset of Fever , 2004, Chest.

[216]  J. Peiris,et al.  Severe acute respiratory syndrome among children. , 2004, Pediatrics.

[217]  Chong-Jen Yu,et al.  Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients , 2004, Emerging infectious diseases.

[218]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[219]  G. Cagney,et al.  Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. , 2004, Blood.

[220]  Z. Ungvari,et al.  Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. , 2004, Physiological genomics.

[221]  Z. Lang,et al.  A clinicopathological study of three cases of severe acute respiratory syndrome (SARS) , 2003, Pathology.

[222]  O. Tsang,et al.  Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong , 2003, Annals of Internal Medicine.

[223]  J. Loscalzo,et al.  Nitric oxide in vascular biology , 2003, Journal of thrombosis and haemostasis : JTH.

[224]  J. Keaney,et al.  The clinical implications of endothelial dysfunction. , 2003, Journal of the American College of Cardiology.

[225]  T. Hintze,et al.  NAD(P)H oxidase-generated superoxide anion accounts for reduced control of myocardial O2 consumption by NO in old Fischer 344 rats. , 2003, American journal of physiology. Heart and circulatory physiology.

[226]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[227]  J. Sung,et al.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.

[228]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[229]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[230]  P. Chan,et al.  Clinical presentations and outcome of severe acute respiratory syndrome in children , 2003, The Lancet.

[231]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[232]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[233]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[234]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[235]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[236]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.

[237]  Daniel Levy,et al.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. , 2003, Circulation.

[238]  N. Petasis,et al.  Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. , 2002, Journal of the American Society of Nephrology : JASN.

[239]  Z. Ungvari,et al.  Aging-Induced Phenotypic Changes and Oxidative Stress Impair Coronary Arteriolar Function , 2002, Circulation research.

[240]  E. Cramer,et al.  Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. , 2002, Blood.

[241]  I. Uthman,et al.  Viral infections and antiphospholipid antibodies. , 2002, Seminars in arthritis and rheumatism.

[242]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[243]  D. Dixon,et al.  Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis , 2001, The Journal of cell biology.

[244]  M. Humbert,et al.  Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension , 2000, Circulation.

[245]  F. Natividad,et al.  Peripheral vascular endothelial dysfunction and apoptosis in old monkeys. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[246]  D. Dixon,et al.  Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[247]  J. Deanfield,et al.  Endothelial dysfunction late after Kawasaki disease. , 1996, Circulation.

[248]  D. Heistad,et al.  Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. , 1993 .

[249]  Robertson Rp.  Seminars in medicine of the Beth Israel Hospital, Boston: Pancreatic and islet transplantation for diabetes--cures or curiosities? , 1992 .

[250]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[251]  J. Loscalzo,et al.  Tissue plasminogen activator promotes platelet disaggregation in plasma. , 1987, The Journal of clinical investigation.

[252]  D. Kromhout,et al.  Treatment of Kawasaki syndrome with intravenous gamma globulin. , 1987 .

[253]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[254]  K. & et al..  HIGH DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1985 .

[255]  H. Nakano,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[256]  Katsuko Sato,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[257]  J. Vane.  Adventures and excursions in bioassay: the stepping stones to prostacylin , 1983, British journal of pharmacology.

[258]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[259]  J. Vane,et al.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. , 1976, Prostaglandins.

[260]  L. Aledort,et al.  Human Platelets , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[261]  Robert A. Campbell,et al.  Platelet Gene Expression and Function in COVID-19 Patients , 2020 .

[262]  G. King,et al.  Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[263]  M. Strauch.  Dissection of the , 1996 .

[264]  J. Ware,et al.  Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator , 1992 .

[265]  T. Murphy,et al.  Risk of subsequent disease among day-care contacts of patients with systemic Hemophilus influenzae type B disease. , 1987, The New England journal of medicine.